Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CAMMOUFLAGE Trial)
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
A Phase 1b/2, Open-label, Multi-center Trial to Evaluate the Safety and Efficacy of CT053 (zevorcabtagene autoleucel) in Patients with Relapsed and/or Refractory MM (LuMMicar-2)
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed Refractory Multiple Myeloma (CAMMA-2)
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, ALL, and 1L HR LBCL
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Tennessee Oncology Partners Through the McKay Institute with OncoveryCare to Raise $4.5M Seed Round from .406 Ventures Blog Post
Tennessee Oncology Launches Rural Telehealth Program to Bridge Digital Divide for Middle Tennessee Cancer Patients Blog Post
McKay Institute for Oncology Transformation and Penn Center for Cancer Care Innovation Unveil New Collaborative Relationship Blog Post
(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally to Patients with Advanced or Metastatic Solid Tumors
A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/?Refractory Classical Hodgkin Lymphoma
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituxiumab in Subjects With B-Cell Lymphoma of Chronic Lymphocytic Leukemia
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-Cell Malignancies.
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monocolonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-Chronic Lymphocytic Leukemia-314)
Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Nashville State Community College, Tennessee Oncology Form Medical Assistant Certification Program Blog Post
Nashville State Community College, Tennessee Oncology Form Medical Assistant Certification Program Blog Post
Tennessee Oncology Launches the Greco-Hainsworth Tennessee Oncology Centers for Research and Appoints Dr. Ian Flinn as Chief Scientific Officer Blog Post
Examining Colorectal and Cervical Cancer Care in Appalachia : A Review of Barriers and Interventions to Cancer Screening, Genetic Services, and Continuity of Care Blog Post
Tennessee Oncology’s Ashley Todd, Clinical Educator, DNP, RN-BC, OCN®, was published in ONS Voice magazine. Blog Post
We’re Proud to Announce Tennessee Oncology Will Serve Cancer Patients in Cookeville in January. Blog Post
Please join us for our monthly virtual CPAN Advocacy Chat – How 340B in Big Health Systems is Hurting Patients Blog Post
Tennessee Oncology Named One of Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot Blog Post
“It’s a great honor to share my friend ‘Hawk’, a fellow Cadet at the Air Force Academy, on this Memorial Day.” – Amy Cox, Nurse Practitioner, Gallatin Clinic Blog Post
“This Memorial Day I remember the American Heroes I met serving in Bosnia, that made the ultimate sacrifice.” – Howard Burris, M.D. Blog Post
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting Blog Post
Tennessee Oncology Expands Adoption of OncoSmartTM Oncology Optimization Solution by iClinicalOps Blog Post
We are so proud of Dr. Jeff Infante, former Tennessee Oncology physician and key investigator for the Drug Development Unit at Sarah Cannon Research Blog Post
“The pace at which new therapies are moving brings hope that all blood cancer patients in the future will have great options for treatment.” – William Donnellan, M.D. Blog Post
Tennessee Oncology Appoints Dr. Stephen Schleicher as Chief Medical Officer and Promotes Dr. Natalie Dickson to President and Chief Strategy Officer Blog Post
Tennessee Oncology Re-Certified With Perfect Score for High-Quality Cancer Care from the Largest Oncology Association in United States Blog Post
Provision Cares Proton Therapy Nashville Achieves Accreditation From World’s Leading Radiation Oncology Society Blog Post
H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium Blog Post
Tennessee Oncology receives perfect quality score while saving Medicare $5 million during last year of Oncology Care Model Blog Post
Tennessee Oncology and Blue Cross Blue Shield of Tennessee Launch New Value-Based Care Initiative Blog Post
Microsoft’s Iksha Herr to Give Keynote Address at AJMC’s 10th Annual Patient-Centered Oncology Care® Conference Blog Post
New Certification Pilot Focuses on Patient-Centered Cancer Care, Equips Practices with Evidence-based Approach to Value-based Care Delivery Blog Post
Woman carries baby for her twin sister who had hysterectomy due to pregnancy-related cancer Blog Post
Podcast: Dr. F. Anthony Greco Explains How Precision Medicine Has Led to Better Treatments for Cancers of Unknown Origins Blog Post
OneOncology and Tennessee Oncology Present Twelve Posters at ASCO Quality and Care Symposium Blog Post
OneOncology and Tennessee Oncology Partnership Fuels Expansion in Chattanooga with Addition of University Oncology Hematology Associates Blog Post
The Role of the Specialty Pharmacist in Transitioning Patients from Cancer Crisis Care to the Community Blog Post
Tennessee Oncology Chosen To Present Six Posters at the American Society of Clinical Oncology (ASCO) Annual Quality of Care Symposium in San Diego, California. Blog Post
The Future of Healthcare: “Healthcare is far too reactive” with Dr. Jeff Patton of OneOncology and Christina D. Warner Blog Post
The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network. Blog Post
Lee Schwartzberg tells us how three practices banded together to adapt to today’s cancer care and data revolution Blog Post
Why and When To Get a Mammogram feat. Dr. Erika Hamilton of Tennessee Oncology – WKRN Nashville News 2 Blog Post
General Atlantic Takes Majority Stake in OneOncology, a Startup for Running Cancer-Doctor Practices Blog Post
Sarah Cannon Promotes William Donnellan, MD, to Director, Leukemia/Myelodysplastic Syndrome Research Blog Post
Tennessee Oncology St.Thomas West’s Dr. Kent Shih and Staff, Country Music Artist Jackie Lee, Rolling Stone Magazine and an Evening at the Opry Blog Post
OUR GOAL IS TO MAKE EVERY PATIENT, EVERY FAMILY AND EVERY REFERRING PHYSICIAN SEE THAT HERE, CARING FOR CANCER PATIENTS IS A PRIVILEGE. Blog Post
Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States? Blog Post
The Tennessee Oncology Network Delivers The Most Advanced Care In Every Community We Serve. Blog Post
Rapid infusion of ofatumumab appears safe and reduces infusion related reactions in patients with relapsed/refractory Chronic Lymphocytic Leukemia Blog Post
Summer Is Scorching But The Lifestyle Is Hard To Beat. Leading Practices Embrace Change Because Our Patients Deserve Our Best. Blog Post
The Tennessee Cancer Consortium invites you and a guest to attend Thriving Together: Living Beyond Metastatic Breast Cancer Blog Post
May Is One Fine Month. Nurse Respect. Clinical Trials Close To Home. Honoring Memorial Day. Blog Post
National Women’s Health Week – May 14 – 20, 2017– When Should You Begin Some Common Cancer Screenings? Blog Post
Would You Like To Support Cancer Research And Do Something Good For Your Health? This Blog’s For You. Blog Post
May Is Skin Cancer Prevention and Awareness Month. Know The Good News And How To Protect Yourself From The Bad. Blog Post
Electronic Medical Records, Practice Will Make Perfect- Patience and Diligence Will Get Us There Blog Post
April Is National Minority Health Month. Minority Populations Often Experience Higher Rates Of Disease. Blog Post
Keep your mind clear and uncluttered to keep your energy level high and your focus on what matters most Blog Post
Tennessee Oncology Receives The Oncology Nurse Society (ONS) 2017 Employer Recognition Award Blog Post
Tennessee Oncology Continually Improves Patient Experience. Pilot Study Reduces ER Visits In Patients Receiving IV Chemo. Blog Post
Local breast cancer survivors take to the runway for, “Heroes in Heels Fashion Show at the Factory in Franklin” Blog Post
Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL Blog Post
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma Blog Post
BlueCross, Tennessee Oncology Pilot Digital Tools To Improve Care, Experience For Cancer Patients Blog Post
